Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immunotherapy has revolutionized advanced cancer treatment, but efficacy varies, with tumors like pancreatic cancer showing limited response to checkpoint inhibitors.
• The tumor microenvironment (TME) contains immunosuppressive cells, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), which hinder anti-tumor immune responses and contribute to immunotherapy resistance.
• Developing strategies to modulate the TME is crucial for improving patient outcomes in various advanced malignancies.

Purpose of the Study:

• This review focuses on immunomodulatory small molecule inhibitors targeting CSF-1R and FAK as potential strategies to enhance immunotherapy efficacy.
• To explore how CSF-1R and FAK inhibitors reprogram the TME and influence immune cell populations.
• To assess the potential of these small molecule inhibitors in overcoming immune escape and potentiating both immunotherapy and traditional cytotoxic therapies.

Main Methods:

• Review of current literature on small molecule inhibitors targeting CSF-1R and FAK in cancer.
• Analysis of the mechanisms by which CSF-1R and FAK inhibitors modulate the TME, including immune cell infiltration and stromal components.
• Examination of preclinical and clinical data regarding the efficacy of these inhibitors in combination with other cancer therapies.

Main Results:

• Small molecule inhibitors of CSF-1R can reprogram TAMs within the TME, promoting T-cell-mediated tumor eradication.
• FAK small molecule inhibitors have been shown to reduce the infiltration of immunosuppressive cells like MDSCs, TAMs, and regulatory T-cells.
• FAK inhibitors also modulate stromal density and cancer stem cells, creating a more permissive TME for anti-tumor immune responses.

Conclusions:

• CSF-1R and FAK inhibitors represent promising therapeutic avenues for overcoming immunotherapy resistance by targeting key components of the immunosuppressive TME.
• These small molecule inhibitors offer a strategy to enhance the effectiveness of existing immunotherapies and traditional cytotoxic treatments.
• Targeting the TME with immunomodulatory small molecules holds significant potential for improving treatment outcomes in patients with advanced malignancies unresponsive to current therapies.